GPCR — Structure Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1888886 ·
Last close
$48.04
Market Cap
$3.41B
52W High
$57.07
52W Low
$35.78
ADV30
726,620
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -89,379,000 | -75,968,000 | 1,508,124,000 | 316,168,000 | 61,030,000 |
| Dec 2025 | 0 | — | 13,740,000 | 33,004,000 | 1,583,918,000 | 799,623,000 | 67,541,000 |
| Sep 2025 | 0 | — | -73,787,000 | -65,712,000 | 832,159,000 | 102,912,000 | 62,140,000 |
| Jun 2025 | 0 | — | -70,451,000 | -61,661,000 | 816,443,000 | 147,024,000 | 44,362,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-222,199,000
Investing CF
$89,796,000
Financing CF
$762,516,000
CapEx
$-3,614,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.53
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-470,300,000
Inventory
—
Receivables
$100,000,000
ST Investments
$646,574,000
EBIT TTM
$-186,809,000
Pretax Income TTM
$-140,687,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -186,809,000 | -141,202,000 | 1,583,918,000 | 67,541,000 | — | -222,199,000 |
| Dec 2024 | 0 | -158,228,000 | -122,526,000 | 903,330,000 | 38,487,000 | — | -116,636,000 |
| Dec 2023 | 0 | -102,775,000 | -89,620,000 | 482,017,000 | 29,051,000 | — | -79,488,000 |
| Dec 2022 | 0 | -52,561,000 | -51,321,000 | 97,845,000 | 212,985,000 | — | -46,120,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.97
Max Pain — expiry 2026-12-18
max pain strike: $42.50 · spot: $48.04 · call oi: 2,508 · put oi: 249
Expected Move to 2026-12-18:
±$22.05
(45.90%) —
implied range
$25.99 –
$70.09
· ATM straddle on $47.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | $3.42B | $35.50 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.44B | $74.34 | — |
| GRTX | Galera Therapeutics, Inc. | $3.38B | $16.28 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.36B | $26.86 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.35B | $9.89 | — |
News headlines (Yahoo Finance, 1h cache)
Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now
2026-07-03 13:41 · Yahoo
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
2026-06-24 11:55 · Yahoo
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)
2026-06-17 15:55 · Yahoo
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron
2026-06-08 03:44 · Yahoo
Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?
2026-06-07 13:18 · Yahoo
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
2026-06-05 20:05 · Yahoo
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
2026-05-26 20:05 · Yahoo
If Viking Therapeutics Is Acquired, Here’s Who Wins
2026-05-26 12:50 · Yahoo
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
2026-05-24 14:39 · Yahoo
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 14:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.